{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53497"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53497","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Targeting endothelial dysfunction in systemic sclerosis: a comparison of current and emerging therapeutics","abstract":"Systemic sclerosis is an autoimmune connective tissue disorder that despite the development of new therapeutics, retains poor long-term outcomes. The progression of the disease involves various organ systems leading to the development of severe complications that deteriorate patient’s quality of life and survival rates. The pathogenesis of the disease is extraordinarily complex and arises from disruptions across multiple systems. Current research emphasizes the role of early initial endothelial injury in the manifestation of systemic sclerosis. Addressing endothelial dysfunction has been an appealing target for the development of new therapeutics. Specifically, research has focused on the endothelin-1 pathway, the nitric oxide pathway, and the prostacyclin pathway for developing new medications. This research has yielded endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators, and prostacyclin analogues as the major classes of medications used to treat this disease. Current therapeutics prove effective in preventing and slowing further endothelial damage but offer little ability to reverse fibrosis related damage. Complications such as pulmonary arterial hypertension, digital ulcers, are Raynaud’s phenomenon are most directly addressed by endothelial targeted therapies. However, other complications such as interstitial lung disease are not addressed by these types of medications. Consequently, the current approach to treatment relies on combining therapies to target complications from multiple avenues. Efficacy of existing therapeutics are similar across the board, however patients may prove individually more receptive to certain therapies. Personalized care that addresses patient’s individual susceptibility through autoantibody and genetic analysis prove effective in achieving better prognoses.","abstract_html":"Systemic sclerosis is an autoimmune connective tissue disorder that despite the development of new therapeutics, retains poor long-term outcomes. The progression of the disease involves various organ systems leading to the development of severe complications that deteriorate patient’s quality of life and survival rates. The pathogenesis of the disease is extraordinarily complex and arises from disruptions across multiple systems. Current research emphasizes the role of early initial endothelial injury in the manifestation of systemic sclerosis. Addressing endothelial dysfunction has been an appealing target for the development of new therapeutics. Specifically, research has focused on the endothelin-1 pathway, the nitric oxide pathway, and the prostacyclin pathway for developing new medications. This research has yielded endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators, and prostacyclin analogues as the major classes of medications used to treat this disease. Current therapeutics prove effective in preventing and slowing further endothelial damage but offer little ability to reverse fibrosis related damage. Complications such as pulmonary arterial hypertension, digital ulcers, are Raynaud’s phenomenon are most directly addressed by endothelial targeted therapies. However, other complications such as interstitial lung disease are not addressed by these types of medications. Consequently, the current approach to treatment relies on combining therapies to target complications from multiple avenues. Efficacy of existing therapeutics are similar across the board, however patients may prove individually more receptive to certain therapies. Personalized care that addresses patient’s individual susceptibility through autoantibody and genetic analysis prove effective in achieving better prognoses.","abstract_has_math":false,"creators":["Kassis, Zack"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Offner, Gwynneth D","Symes, Karen"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T20:42:02Z","subjects":["Medicine","Endothelial dysfunction","Endothelial injury","Systemic sclerosis"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/53497","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53497","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53497","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Offner, Gwynneth D","Symes, Karen"]},{"key":"dc:creator","label":"Author","values":["Kassis, Zack"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-09-18T15:33:14Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2026-09-18T15:33:14Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-09-16T16:15:27Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicine","Endothelial dysfunction","Endothelial injury","Systemic sclerosis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53497"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2026"]},{"key":"dc:description.abstract","label":"Abstract","values":["Systemic sclerosis is an autoimmune connective tissue disorder that despite the development of new therapeutics, retains poor long-term outcomes. The progression of the disease involves various organ systems leading to the development of severe complications that deteriorate patient’s quality of life and survival rates. The pathogenesis of the disease is extraordinarily complex and arises from disruptions across multiple systems. Current research emphasizes the role of early initial endothelial injury in the manifestation of systemic sclerosis. Addressing endothelial dysfunction has been an appealing target for the development of new therapeutics. Specifically, research has focused on the endothelin-1 pathway, the nitric oxide pathway, and the prostacyclin pathway for developing new medications. This research has yielded endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators, and prostacyclin analogues as the major classes of medications used to treat this disease. Current therapeutics prove effective in preventing and slowing further endothelial damage but offer little ability to reverse fibrosis related damage. Complications such as pulmonary arterial hypertension, digital ulcers, are Raynaud’s phenomenon are most directly addressed by endothelial targeted therapies. However, other complications such as interstitial lung disease are not addressed by these types of medications. Consequently, the current approach to treatment relies on combining therapies to target complications from multiple avenues. Efficacy of existing therapeutics are similar across the board, however patients may prove individually more receptive to certain therapies. Personalized care that addresses patient’s individual susceptibility through autoantibody and genetic analysis prove effective in achieving better prognoses."]},{"key":"dc:title","label":"Title","values":["Targeting endothelial dysfunction in systemic sclerosis: a comparison of current and emerging therapeutics"]}]}],"canonical_facts":{"dc:contributor.advisor":["Offner, Gwynneth D","Symes, Karen"],"dc:creator":["Kassis, Zack"],"dc:date.accessioned":["2026-09-18T15:33:14Z"],"dc:date.available":["2026-09-18T15:33:14Z"],"dc:date.issued":["2026"],"dc:date.updated":["2026-09-16T16:15:27Z"],"dc:description":["2026"],"dc:description.abstract":["Systemic sclerosis is an autoimmune connective tissue disorder that despite the development of new therapeutics, retains poor long-term outcomes. The progression of the disease involves various organ systems leading to the development of severe complications that deteriorate patient’s quality of life and survival rates. The pathogenesis of the disease is extraordinarily complex and arises from disruptions across multiple systems. Current research emphasizes the role of early initial endothelial injury in the manifestation of systemic sclerosis. Addressing endothelial dysfunction has been an appealing target for the development of new therapeutics. Specifically, research has focused on the endothelin-1 pathway, the nitric oxide pathway, and the prostacyclin pathway for developing new medications. This research has yielded endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators, and prostacyclin analogues as the major classes of medications used to treat this disease. Current therapeutics prove effective in preventing and slowing further endothelial damage but offer little ability to reverse fibrosis related damage. Complications such as pulmonary arterial hypertension, digital ulcers, are Raynaud’s phenomenon are most directly addressed by endothelial targeted therapies. However, other complications such as interstitial lung disease are not addressed by these types of medications. Consequently, the current approach to treatment relies on combining therapies to target complications from multiple avenues. Efficacy of existing therapeutics are similar across the board, however patients may prove individually more receptive to certain therapies. Personalized care that addresses patient’s individual susceptibility through autoantibody and genetic analysis prove effective in achieving better prognoses."],"dc:identifier.uri":["https://hdl.handle.net/2144/53497"],"dc:language.iso":["en_US"],"dc:subject":["Medicine","Endothelial dysfunction","Endothelial injury","Systemic sclerosis"],"dc:title":["Targeting endothelial dysfunction in systemic sclerosis: a comparison of current and emerging therapeutics"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:42:02Z"}